ClinicalTrials.gg
WithdrawnNCT07638566emlightUpdated Nov 13, 2026

A Study to Assess the Correct Dose, Safety and Efficacy of Empasiprubart in Adolescent Participants Aged 12 to Less Than 18 Years With Chronic Inflammatory Demyelinating Polyradiculoneuropathy

A Phase 2/3 interventional study of Empasiprubart IV in Chronic Inflammatory Demyelinating Polyradiculoneuropathy, CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy) and CIDP, sponsored by argenx. Withdrawn. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by argenx · Phase 2/3, Interventional, and Treatment

Why this study was withdrawn
An alternative study design is under consideration.
Updated Nov 13, 2026Now WithdrawnEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
0
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Study summary

The main purpose of the study is to determine the correct dose of empasiprubart in adolescent participants. It also aims to evaluate if empasiprubart may work and how safe it is for the use in children living with CIDP.

The study consists of an open label treatment phase where participants will receive empasiprubart for up to 27 months approximately. After the final dose of empasiprubart, participants will enter a safety follow-up period for up to 14 months approximately.

The overall study duration for each participant is up to 43 months.

More information can be found here: clinicaltrials.argenx.com/emlight

02

Conditions studied

  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • CIDP (Chronic Inflammatory Demyelinating Polyradiculoneuropathy)
  • CIDP
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)
03

In context

Polyradiculoneuropathy, Chronic Inflammatory Demyelinating

137 studies on the registry are indexed under Polyradiculoneuropathy, Chronic Inflammatory Demyelinating; 50 are open to participants now.

Browse Polyradiculoneuropathy, Chronic Inflammatory Demyelinating studies →

Lead sponsor

argenx is the lead sponsor of 87 studies on the registry; 28 are open to participants now.

Of its 22 completed or terminated interventional studies of FDA-regulated products, 16 (73%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Is aged 12 to \<18 years.
  • Meets criteria for CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021).
  • Has a diagnosis of either typical CIDP or 1 of the following CIDP variants: motor CIDP (including motor-predominant CIDP), multifocal CIDP (also known as Lewis-Sumner syndrome), focal CIDP, or distal CIDP.

Exclusion criteria

Exclusion Criteria:

  • Possible CIDP based on EAN/PNS Task Force CIDP guidelines, second revision (2021).
  • Sensory CIDP (including sensory-predominant CIDP).
  • Besides the indication under study, known disease or any medical condition that would interfere with an accurate assessment of clinical symptoms of CIDP, or that puts the participant at undue risk.
  • Prior use of other long-acting immunomodulatory treatment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Empasiprubart IV

    Participants will receive empasiprubart IV

    Biological: Empasiprubart IV

Interventions

06

What researchers measure

Primary outcomes

  1. Empasiprubart serum concentrations as input for a population PK-driven analysis to determine the effect of age and body size on CL and Vd

    CL = Clearance; Vd = apparent volume of distribution.

    Time frame: Up to 8 weeks

  2. Free and total C2 levels as input for PK/PD modeling analysis

    C2 = complement component 2.

    Time frame: Up to 8 weeks

Secondary outcomes

  1. Incidence of AEs, SAEs and AESIs

    AE = Adverse event ; SAE = Serious adverse event ; AESI = Adverse event of special interest.

    Time frame: Up to 180 weeks

  2. Empasiprubart serum concentrations over time

    Time frame: Up to 180 weeks

  3. Percentage reductions from baseline of free and total C2 levels over time

    C2 = complement component 2.

    Time frame: Up to 180 weeks

  4. Incidence of ADA and NAb against empasiprubart in serum

    ADA = antidrug antibody(ies); NAb = neutralizing antibody(ies).

    Time frame: Up to 180 weeks

07

Study locations

No study locations are listed for this record.

08

References and documents

Related links

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Sep 2026; primary completion for Apr 2028, 19 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 5, 2026
First posted
Jun 10, 2026
StartEst.
Sep 2026
Primary completionEst.
Apr 2028
CompletionEst.
Aug 2031
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Withdrawn An alternative study design is under consideration.
changed Nov 13, 2026
Enrollment
6 (estimated)→0 (actual)
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Not yet recruiting→Withdrawn
    Why stopped An alternative study design is under consideration.
    Enrollment 6 (estimated)→0 (actual)
    + 3 other changes: identifiers, verification date and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07638566
Lead sponsor
argenx
Responsible party
Sponsor
First posted
Jun 10, 2026
Start date
Sep 2026 (estimated)
Primary completion
Apr 2028 (estimated)
Completion
Aug 2031 (estimated)
Last update
Nov 13, 2026

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Empasiprubart

Start the discussion